Literature DB >> 20643156

Bites by the colubrid snake Philodryas patagoniensis: a clinical and epidemiological study of 297 cases.

Carlos R de Medeiros1, Priscila L Hess, Alessandra F Nicoleti, Leticia R Sueiro, Marcelo R Duarte, Selma M de Almeida-Santos, Francisco O S França.   

Abstract

We retrospectively analyzed 297 proven cases of Philodryas patagoniensis bites admitted to Hospital Vital Brazil (HVB), Butantan Institute, São Paulo, Brazil, between 1959 and 2008. Only cases in which the causative animal was brought and identified were included. Part of the snakes brought by the patients was still preserved in the collection maintained by the Laboratory of Herpetology. Of the 297 cases, in 199 it was possible to describe the gender of the snake, and seventy three (61.3%) of them were female. The length of snakes (snout-vent length) ranged from 160 to 1080 mm. In 117 snakes their state of preservation enabled the dissection and examination of their stomach contents. The stomach was empty in 106 snakes (89.1%). Most bites occurred in the seasons of spring and summer (n = 196, 66.0%) and during warmer periods of the day. The mean age of the victims was 24.1 +/- 15.1 years old and 206 (69.4%) patients were men. Around 92% of the patients sought medical care within 6 h after the bite. Both lower (n = 188, 63.3%) and upper limbs (n = 102, 34.3%) were most frequently bitten, especially the feet and hands (n = 205, 69.0%). The local clinical manifestations were pain (n = 151, 50.8%), transitory bleeding (n = 106, 35.7%), erythema (n = 47, 15.8%) and edema (n = 39, 13.1%). Ecchymosis was not observed. Only 7 (2.4%) patients reported systemic symptoms characterized by mild dizziness and 88 patients (29.6%) showed no evidence of envenoming. The whole blood clotting time was performed in 76 (25.6%) patients on admission and all of them had coagulable blood. Supportive treatment was offered to only 13.4% of patients, namely administration of antihistamines (n = 19, 6.4%) and analgesics (n = 12, 4.1%). Eight patients (2.7%) were mistreated with Bothrops antivenom before their admission to HVB. No sequels or relevant complications were observed in patients, and the prognostic was benign. Therefore, although P. patagoniensis accidents can cause mild local symptomatology, it is very important that health professionals know how to make the correct diagnosis to avoid unnecessary use of antivenom. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643156     DOI: 10.1016/j.toxicon.2010.07.006

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Clinical toxinology.

Authors:  Julian White
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

2.  A case of envenomation by the false fer-de-lance snake Leptodeira annulata (Linnaeus, 1758) in the department of La Guajira, Colombia.

Authors:  Teddy Angarita-Sierra; Alejandro Montañez-Méndez; Tatiana Toro-Sánchez; Ariadna Rodríguez-Vargas
Journal:  Biomedica       Date:  2020-03-01       Impact factor: 0.935

3.  Identifying the snake: First scoping review on practices of communities and healthcare providers confronted with snakebite across the world.

Authors:  Isabelle Bolon; Andrew M Durso; Sara Botero Mesa; Nicolas Ray; Gabriel Alcoba; François Chappuis; Rafael Ruiz de Castañeda
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

4.  Patagonin-CRISP: Antimicrobial Activity and Source of Antimicrobial Molecules in Duvernoy's Gland Secretion (Philodryas patagoniensis Snake).

Authors:  Juliana Cuoco Badari; Andrea Díaz-Roa; Marisa Maria Teixeira Rocha; Ronaldo Zucatelli Mendonça; Pedro Ismael da Silva Junior
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

Review 5.  Philodryas (Serpentes: Dipsadidae) Envenomation, a Neglected Issue in Chile.

Authors:  Félix A Urra; Alejandro Bruno Miranda-Calle; Ramiro Araya-Maturana
Journal:  Toxins (Basel)       Date:  2019-11-29       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.